HomeCompareLPUSF vs PFE

LPUSF vs PFE: Dividend Comparison 2026

LPUSF yields 4.14% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $11.2K in total portfolio value· pulled ahead in Year 10
10 years
LPUSF
LPUSF
● Live price
4.14%
Share price
$3.31
Annual div
$0.14
5Y div CAGR
16.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$38.3K
Annual income
$3,467.67
Full LPUSF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — LPUSF vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLPUSFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LPUSF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LPUSF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LPUSF
Annual income on $10K today (after 15% tax)
$351.81/yr
After 10yr DRIP, annual income (after tax)
$2,947.52/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $19,372.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LPUSF + PFE for your $10,000?

LPUSF: 50%PFE: 50%
100% PFE50/50100% LPUSF
Portfolio after 10yr
$44.0K
Annual income
$14,863.20/yr
Blended yield
33.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

LPUSF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
3.8
Piotroski
8/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LPUSF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLPUSFPFE
Forward yield4.14%6.13%
Annual dividend / share$0.14$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR16.8%13.2%
Portfolio after 10y$38.3K$49.6K
Annual income after 10y$3,467.67$26,258.71
Total dividends collected$15.2K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: LPUSF vs PFE ($10,000, DRIP)

YearLPUSF PortfolioLPUSF Income/yrPFE PortfolioPFE Income/yrGap
1$11,183$483.43$9,153$693.39+$2.0KLPUSF
2$12,556$590.16$8,593$849.25+$4.0KLPUSF
3$14,159$723.30$8,336$1,066.78+$5.8KLPUSF
4$16,040$890.30$8,437$1,384.80+$7.6KLPUSF
5$18,264$1,100.98$9,013$1,875.40+$9.3KLPUSF
6$20,911$1,368.43$10,306$2,680.72+$10.6KLPUSF
7$24,085$1,710.25$12,820$4,101.38+$11.3KLPUSF
8$27,921$2,150.26$17,673$6,826.70+$10.2KLPUSF
9$32,597$2,721.06$27,543$12,591.86+$5.1KLPUSF
10← crossover$38,346$3,467.67$49,560$26,258.71$11.2KPFE

LPUSF vs PFE: Complete Analysis 2026

LPUSFStock

Tyman plc supplies engineered fenestration components and access solutions to the construction industry. The company designs and manufactures products that enhance the comfort, sustainability, security, safety, and aesthetics of residential homes and commercial buildings. It operates through three divisions: Tyman North America, Tyman UK & Ireland, and Tyman International. The Tyman North America division manufactures window and door hardware components, extrusions, and sealing systems. It offers single and multipoint locking systems, decorative handle trim sets, and precision rollers; operators, tie bar/locks, and hinges for casement and awning applications; and locks/keepers, integrated tilt latches, rollers, balance systems, seals, and extruded profiles for hung and sliding window applications, as well as a range of specialty access and safety products, including smoke vents, roof access hatches, floor access doors, and ladder posts. The Tyman UK & Ireland division engages in the design, development, manufacture, and distribution of decorative and security hardware and smart ware for residential doors and windows under the ERA and Fab & Fix brands. It also distributes weather seals for residential and commercial fenestration applications, as well as Giesse branded aluminum hardware; and designs and supplies architectural door hardware for commercial applications, as well as offers manufacturing solution for roof, ceiling, wall, and floor access products to the commercial construction industry. The Tyman International division provides hardware and seals to the door and window industry. This segment provides its products under the Schlegel, Giesse, and Reguitti brands. The company was formerly known as Lupus Capital plc and changed its name to Tyman plc in February 2013. Tyman plc was incorporated in 1993 and is headquartered in London, the United Kingdom.

Full LPUSF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this LPUSF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LPUSF vs SCHDLPUSF vs JEPILPUSF vs OLPUSF vs KOLPUSF vs MAINLPUSF vs JNJLPUSF vs MRKLPUSF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.